What is Citius Oncology, Inc.'s accounts receivable?

Citius Oncology, Inc. (CTOR) reported accounts receivable of $1.08M in Q1 2026.

What does accounts receivable mean?

Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.

Citius Oncology, Inc. CTOR Accounts Receivable

Accounts Receivable at other companies

Merck & Co.MRK

$12.21B+13.2%

Delcath SystemsDCTH

$14.16M+1.6%

Iovance Biotherapeutics, Inc.IOVA

$81.76M+15.3%

ImmunityBio, Inc.IBRX

$43.27M+154%

Gilead SciencesGILD

$5.54B+5.5%

United TherapeuticsUTHR

$312M-3.1%

Other financials

Income statement

See full

Revenue$1.7M—

Gross profit$1.3M—

Operating income-$28.6M-283%

Net income-$26.6M-244%

EPS (diluted)-$0.27-145%

Balance sheet

See full

Cash & equivalents$2.6M+2,350,466%

Total equity$35.3M-1.0%

Total assets$100.7M+10.1%

Cash flow

See full

Operating cash flow-$3.8M-179%

Valuation

See full

Market cap$60.45M-74.7%

Returns & leverage

See full

Return on equity-119.9%+46.7pp

Current ratio0.5×+0.1×

Where this comes from

Reported directly by Citius Oncology, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.

The official record: Citius Oncology, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Citius Oncology, Inc.'s accounts receivable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Citius Oncology, Inc.'s accounts receivable?: Citius Oncology, Inc. (CTOR) reported accounts receivable of $1.08M in Q1 2026.
What does accounts receivable mean?: Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.